| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
55,234 |
40,916 |
$2.07M |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
14,670 |
13,512 |
$1.16M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
15,543 |
14,321 |
$601K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
4,499 |
4,389 |
$314K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
20,807 |
19,073 |
$280K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,893 |
3,821 |
$268K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
10,355 |
8,152 |
$223K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,126 |
2,893 |
$213K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,598 |
2,531 |
$181K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
16,303 |
6,829 |
$174K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,246 |
1,200 |
$93K |
| 87634 |
|
1,446 |
1,288 |
$84K |
| 99429 |
|
2,011 |
1,982 |
$59K |
| 99382 |
|
494 |
493 |
$44K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,263 |
2,535 |
$40K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,716 |
5,186 |
$37K |
| 87807 |
|
2,918 |
2,644 |
$32K |
| 99381 |
|
389 |
383 |
$29K |
| 92558 |
|
3,570 |
3,552 |
$27K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
336 |
327 |
$22K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
2,407 |
2,380 |
$19K |
| 90461 |
|
4,673 |
3,933 |
$17K |
| 99383 |
|
200 |
200 |
$17K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
249 |
234 |
$12K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
250 |
246 |
$8K |
| 83655 |
|
520 |
519 |
$5K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,142 |
1,478 |
$3K |
| 81002 |
|
1,035 |
1,000 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
45 |
44 |
$3K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
59 |
59 |
$2K |
| 99384 |
|
12 |
12 |
$1K |
| 80053 |
Comprehensive metabolic panel |
127 |
124 |
$1K |
| 86318 |
|
73 |
73 |
$1K |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
7,869 |
7,775 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
60 |
60 |
$730.01 |
| 86580 |
|
77 |
77 |
$551.18 |
| 84030 |
|
107 |
102 |
$495.21 |
| 96160 |
|
456 |
451 |
$485.89 |
| 97802 |
|
2,311 |
2,289 |
$475.47 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
162 |
161 |
$387.51 |
| 80061 |
Lipid panel |
25 |
25 |
$281.25 |
| 90619 |
|
384 |
384 |
$152.58 |
| 99051 |
|
741 |
679 |
$127.71 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
12 |
12 |
$97.92 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
640 |
619 |
$75.58 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
55 |
54 |
$46.79 |
| 85018 |
|
321 |
321 |
$11.94 |
| 90686 |
|
1,407 |
1,405 |
$0.36 |
| 90620 |
|
397 |
396 |
$0.10 |
| 90715 |
|
343 |
340 |
$0.05 |
| 90688 |
|
103 |
103 |
$0.05 |
| 90647 |
|
2,175 |
2,164 |
$0.03 |
| 90651 |
|
558 |
557 |
$0.03 |
| 90716 |
|
239 |
237 |
$0.02 |
| 90707 |
|
243 |
241 |
$0.01 |
| 90734 |
|
262 |
260 |
$0.01 |
| 90710 |
|
576 |
575 |
$0.00 |
| 90670 |
|
1,743 |
1,732 |
$0.00 |
| 90633 |
|
1,195 |
1,189 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
2,505 |
2,476 |
$0.00 |
| 90700 |
|
339 |
336 |
$0.00 |
| 90649 |
|
140 |
138 |
$0.00 |
| 3120F |
|
20,567 |
18,851 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
5,499 |
5,429 |
$0.00 |
| 99174 |
|
3,905 |
3,875 |
$0.00 |
| 90680 |
|
1,563 |
1,557 |
$0.00 |
| 90677 |
|
502 |
500 |
$0.00 |
| 90723 |
|
1,631 |
1,624 |
$0.00 |
| 90696 |
|
370 |
370 |
$0.00 |
| 3330F |
|
32 |
32 |
$0.00 |
| G0010 |
Administration of hepatitis b vaccine |
492 |
487 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
105 |
102 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
69 |
69 |
$0.00 |
| 90697 |
|
14 |
14 |
$0.00 |